GlassScriptPhysician profile
Sandy D Sublett
NPI 1932202728
$4,451.92
in general payments reported to CMS, 2019-2025
29 companies · $1,267 in 2025
The $1,267 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $671 · 2022: $787 · 2023: $702 · 2024: $1,025 · 2025: $1,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,994.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $511.53 | 2021-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $508.89 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $404.44 | 2021-2025 | Verquvo, Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.03 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $249.09 | 2021-2023 | Xarelto |
| Pfizer INC. | $237.46 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $234.49 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $214.79 | 2021-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $204.70 | 2021-2025 | |
| Novo Nordisk INC | $196.74 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $173.74 | 2021-2024 | Lifevest |
| Abbott Laboratories | $148.91 | 2021-2025 | Assurity, Merlin@Home, Gallant |
| Terumo Medical Corporation | $126.41 | 2025 | Azur Cx Detachable |
| United Therapeutics Corporation | $122.47 | 2021-2025 | Tyvaso |
| Lexicon Pharmaceuticals, INC. | $109.76 | 2023-2024 | Inpefa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $109.02 | 2024 | |
| Shockwave Medical, INC | $105.97 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Philips North America LLC | $82.80 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $78.90 | 2024-2025 | Camzyos |
| Alnylam Pharmaceuticals INC. | $66.89 | 2025 | Amvuttra |
| Medtronic, INC. | $50.48 | 2024-2025 | Linq II |
| Esperion Therapeutics, INC. | $49.43 | 2022-2024 | Nexletol |
| Lantheus Medical Imaging, INC. | $43.90 | 2021-2025 | |
| Boston Scientific Corporation | $36.81 | 2021-2022 | |
| Glaxosmithkline, LLC. | $34.04 | 2025 | Arexvy, Shingrix |
| Chiesi USA, INC. | $24.26 | 2024 | Kengreal |
| Biosense Webster, INC. | $22.71 | 2024 | Carto 3 |
| Genzyme Corporation | $18.32 | 2025 | |
| Altathera Pharmaceuticals LLC | $17.94 | 2025 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Sublett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.